Almac provides a comprehensive range of integrated services from research through pharmaceutical and clinical development to commercialisation of product.
New developments
At Almac’s global headquarters, $1m has been invested in a dedicated mass spectrometry lab, while expansion of its manufacturing capacity is underway. Reactor vessels with cleanroom product isolation and drying equipment will allow Highly Potent API manufacture up to 600kg batch size. Additionally, the company’s biocatalyst group has experienced growth in building block supply, evolution and commercial manufacture projects as well as metabolite synthesis.
Almac also recently dedicated $10m to a new non-GMP pharmaceutical development facility enhancing speed and flexibility to provide streamlined progression between development and GMP phases of projects. A further $10m investment was made in a stateof-the-art, 100,000ft2 facility in Audubon, PA now offering quality, flexible US commercial packaging solutions for solid oral and sterile biopharmaceutical drug products.
Hall 10 Stand E41
